Research, development and public production of pharmaceuticals in Argentina

Biosimilars/Research | Posted 22/10/2021 post-comment0 Post your comment

Under the current research and development model, the pharmaceutical industry has switched its focus towards the therapeutic areas that offer the greatest commercial benefit, which are often not aligned with public health needs. Consequently, it has ceased to be the great innovative industry that it had been during the last century.

126 AA010686

The consequences are on display. The so-called ‘me-too’ or ‘follow-on’ drugs and evergreening* practices, complicate and delay the commercialization of generics and biosimilars that compete with originator brand-name products. Thus, in recent years, only a quarter of the drugs approved by the regulatory agencies represent a real therapeutic advance [1].

On the other hand, most of the research funding that has led to the discovery of the greatest radical innovations in the pharmaceutical field is public, that is, the innovative research is paid with taxpayers’ money [2]. This concern was described towards the end of the 20th century after analysing the added value of the new molecular entities, and it has been corroborated recently during the development of vaccines, diagnostic methods and treatments for the SARS-CoV-2 pandemic.

In Argentina, this model is replicated to a large extent. The commercialization of most drugs is approved through a regulatory reliance process, that is, by accepting an evaluation carried out by the regulatory agency of a country considered to have high public health surveillance.

Argentinian researchers discuss the implications of the current pseudo-innovation model for a country like Argentina, as well as the public policies, focused on the Public Production of Medicines (PPM) that could promote universal access and respond to the country’s health needs, which was published in Ciencia Tecnología y Política [3]. Several states have had PPM programmes for several decades and, in recent years, the strategy has become a matter of discussion in other countries such as the UK.

Argentina has approximately 40 institutions distributed throughout the country that focus on PPM. In this context, medicines are considered a social good, leading to the adoption of a production and marketing logic that entails several benefits. These laboratories supply the public health sector with drugs and medical devices at prices ostensibly lower than those offered by private industry. In a world in crisis, such as the current one, having public production capacity allows the country not only to respond to local health problems but also to ensure the supply of medicines regardless of the global geopolitical situation. It contributes to reducing the trade deficit by limiting the import of manufactured products and results in foreign exchange savings in a country with recurring balance of payments problems. The creation, in 2014, of the Agencia Nacional de Laboratorios Públicos (ANLAP: The National Agency of Public Laboratories) aimed to improve the articulation and coordination of the public laboratories through the establishment and strengthening of a network capable of responding to the health needs of the public system.

The authors concluded that leaving the last stages of research and development of new medicines and their production in the hands of the private pharmaceutical industry has allowed companies to prioritize their economic benefits and maximize profits for their shareholders. This in turn has reduced their interest in the development of new treatments to respond to public health needs. There are alternatives to this model, including the PPM.

*The practice of evergreening is where pharmaceutical companies make small patentable changes to existing products with soon-to-expire patents.

Conflict of interest
The authors of the research paper [3] declared that there was no conflict of interest.

Abstracted by Federico Piñeiro, Nicolás Chiarante and Matías Zelaya, Instituto de Salud Colectiva, Universidad Nacional de Lanus, Buenos Aires, Argentina.

Editor’s comment
Readers interested to learn more about biosimilars in Argentina are invited to visit to view the following manuscripts published in GaBI Journal:

Prescribing practices for biosimilars: questionnaire survey findings from physicians in Argentina, Brazil, Colombia and Mexico

Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
2.0 – CiteScoreTracker 2021 (Last updated on 5 October 2021)

Submit a manuscript to GaBI Journal

Related article
Similar biotherapeutic products approved and marketed in Latin America


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Grupos de gastroenterólogos argentinos emiten su posicionamiento sobre el uso de biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Grupos de gastroenterólogos argentinos emiten su posicionamiento sobre el uso de biosimilares

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. New products and new indications in 2016: A system that favours imitation over the pursuit of real progress. Prescrire Int. 2017;26(182):136-9.
2. Mazzucato, M. El Estado emprendedor: mitos del sector público frente al privado. Barcelona: RBA Economía. Anthem Press. 2014;1-47.
3. Piñeiro F, Chiarante N., Zelaya M. Sobre la investigación, desarrollo y producción pública de nuevos medicamentos. Ciencia Tecnología y Política. 2020;3(4):1-8.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010